ArticleBMC microbiology2025
Multifunctional nanostructured lipid carriers encapsulating Bacillus megaterium supernatant and magnetic nanoparticles for combating methicillin-resistant Staphylococcus aureus and cancer cells.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combating multidrug-resistant pathogens, breast cancer (MCF-7) and hepatocellular carcinoma (HepG2) using biofabricated zinc oxide nanoparticles.Scientific reports · 2026Article
- Multifunctional activity of Mentha piperita essential oil nanoemulsion against Helicobacter pylori.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructured lipid carriers (NLCs), liposomes, and microemulsions represent significant advancements in drug delivery systems. This study aimed to synthesize NLCs encapsulating Bacillus megaterium supernatant (BMS) and magnetic nanoparticles (MNPs) for potential application against MRSA and cancer cells. The NLCs were prepared using the emulsification-solvent evaporation technique and loaded with BMS and MNPs to form NLC-BMS-MNPs. Characterization of the NLC-BMS-MNPs was performed using X-ray diffraction (XRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential. The NLC-BMS-MNPs exhibited a spherical morphology with an average size of 74.45 nm, a polydispersity index (PDI) of 0.350, and a zeta potential of − 4.44 mV. NLC-BMS-MNPs demonstrated antibacterial activity, with minimum inhibitory concentrations (MICs) ranging from 7.5 to 30 µg/mL. They also significantly downregulated the expression of biofilm-associated genes fnbA, icaA, and cna, with fold changes ranging from − 1.9 to -3, -2 to 3, -4 to5.2, respectively (P < 0.0001). Furthermore, the formulation showed antioxidant activity, with IC₅₀ values of 299 µg/mL and 521 µg/mL in DPPH and ABTS assays, respectively. Additionally, NLC-BMS-MNPs exhibited selective cytotoxicity toward cancer cells. HepG2 and MCF-7 cells displayed significantly reduced viability, with IC₅₀ values of 13.74 ± 0.02 µg/mL and 19.12 ± 0.51 µg/mL, respectively, compared to normal Vero and HFB-4 cells, which showed IC₅₀ values of 36.1 ± 0.65 µg/mL and 33.45 ± 2.29 µg/mL. In conclusion, NLC-BMS-MNPs represent a promising multifunctional nanomaterial with potential applications in both antimicrobial and anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.